{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:33:55Z","timestamp":1791855235818,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T00:00:00Z","timestamp":1452124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40265-015-0535-2","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T10:32:32Z","timestamp":1452162752000},"page":"255-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia"],"prefix":"10.1007","volume":"76","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,7]]},"reference":[{"key":"535_CR1","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00198-015-3272-1","volume":"26","author":"ML Bianchi","year":"2015","unstructured":"Bianchi ML. Hypophosphatasia: an overview of the disease and its treatment. Osteoporos Int. 2015;26:2743\u201357.","journal-title":"Osteoporos Int."},{"key":"535_CR2","author":"JL Mill\u00e1n","year":"2015","unstructured":"Mill\u00e1n JL, Whyte MP. Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int. 2015. doi: 10.1007\/s00223-015-0079-1 .","journal-title":"Calcif Tissue Int."},{"issue":"10","key":"535_CR3","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/jbmr.454","volume":"26","author":"D Wenkert","year":"2011","unstructured":"Wenkert D, McAlister WH, Coburn SP, et al. Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Metab. 2011;26(10):2389\u201398.","journal-title":"J Bone Miner Metab."},{"key":"535_CR4","doi-asserted-by":"crossref","unstructured":"Weber T, Sawyer E, Moseley S, et al. Burden of disease in children with hypophosphatasia: results from patient-reported surveys [abstract no. P119]. In: 7th International Conference on Children\u2019s Bone Health; 2015.","DOI":"10.1530\/boneabs.4.P119"},{"key":"535_CR5","doi-asserted-by":"crossref","unstructured":"Whyte M, Leung E, Wilcox W, et al. Hypophosphatasia: a retrospective natural history study of the severe perinatal and infantile forms [abstract no. 200]. In: Joint meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research; 2014.","DOI":"10.1530\/boneabs.3.PP364"},{"key":"535_CR6","doi-asserted-by":"crossref","unstructured":"Weber T, Sawyer E, Moseley S, et al. Fracture and surgical burden in pediatric and adult patients with hypophosphatasia: results from patient-reported outcome surveys [abstract no. 516]. In: American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress; 2015.","DOI":"10.1530\/boneabs.4.P119"},{"issue":"Suppl 2","key":"535_CR7","first-page":"380","volume":"10","author":"C Rockman-Greenberg","year":"2013","unstructured":"Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(Suppl 2):380\u20138.","journal-title":"Pediatr Endocrinol Rev."},{"key":"535_CR8","doi-asserted-by":"crossref","unstructured":"Weber T, Sawyer E, Moseley S, et al. Burden of disease in adult patients with hypophosphatasia: results from patient-reported outcome surveys [abstract no. FRI-240]. In: 97th Endocrine Society Annual Meeting; 2015.","DOI":"10.1530\/boneabs.4.P119"},{"issue":"5","key":"535_CR9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0002-9343(57)90124-9","volume":"22","author":"D Fraser","year":"1957","unstructured":"Fraser D. Hypophosphatasia. Am J Med. 1957;22(5):730\u201346.","journal-title":"Am J Med."},{"issue":"1","key":"535_CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/geno.1993.1305","volume":"17","author":"CR Greenberg","year":"1993","unstructured":"Greenberg CR, Taylor CLD, Haworth JC, et al. A homoallelic Gly317\u00a0\u2192\u00a0Asp mutation in APL causes the perinatal (lethal) form of hypophosphatasia in Canadian Mennonites. Genomics. 1993;17(1):215\u20137.","journal-title":"Genomics."},{"key":"535_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/8904_2013_224","volume":"11","author":"ECW Leung","year":"2013","unstructured":"Leung ECW, Mhanni AA, Reed M, et al. Outcome in perinatal hypophosphatasia in Manitoba Mennonites: a retrospective cohort analysis. JIMD Rep. 2013;11:73\u20138.","journal-title":"JIMD Rep."},{"key":"535_CR12","doi-asserted-by":"crossref","unstructured":"Mornet E. Hypophosphatasia. Orphanet J Rare Dis. 2007;2(40).","DOI":"10.1186\/1750-1172-2-40"},{"key":"535_CR13","unstructured":"European Medicines Agency. Strensiq 40\u00a0mg\/mL solution for injection, Strensiq 100\u00a0mg\/mL solution for injection: summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 20 July 2015."},{"issue":"3","key":"535_CR14","first-page":"164","volume":"8","author":"JL Mill\u00e1n","year":"2012","unstructured":"Mill\u00e1n JL, Plotkin H. Hypophosphatasia: pathophysiology and treatment. Actual Osteol. 2012;8(3):164\u201382.","journal-title":"Actual Osteol."},{"issue":"10","key":"535_CR15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904\u201313.","journal-title":"N Engl J Med."},{"issue":"3","key":"535_CR16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ymgme.2006.02.012","volume":"88","author":"T Nishioka","year":"2006","unstructured":"Nishioka T, Tomatsu S, Gutierrez MA, et al. Enhancement of drug delivery to bone:characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab. 2006;88(3):244\u201355.","journal-title":"Mol Genet Metab."},{"issue":"8","key":"535_CR17","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/jbmr.1619","volume":"27","author":"MC Yadav","year":"2012","unstructured":"Yadav MC, de Oliveira RC, Foster BL, et al. Enzyme replacement prevents enamel defects in hypophosphatasia mice. J Bone Miner Res. 2012;27(8):1722\u201334.","journal-title":"J Bone Miner Res."},{"issue":"2","key":"535_CR18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bone.2011.03.770","volume":"49","author":"MC Yadav","year":"2011","unstructured":"Yadav MC, Lemire I, Leonard P, et al. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone. 2011;49(2):250\u20136.","journal-title":"Bone."},{"issue":"6","key":"535_CR19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1359\/jbmr.071213","volume":"23","author":"JL Mill\u00e1n","year":"2008","unstructured":"Mill\u00e1n JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008;23(6):777\u201387.","journal-title":"J Bone Miner Res."},{"issue":"4","key":"535_CR20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0022034510393517","volume":"90","author":"MD McKee","year":"2011","unstructured":"McKee MD, Nakano Y, Masica DL, et al. Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia. J Dent Res. 2011;90(4):470\u20136.","journal-title":"J Dent Res."},{"key":"535_CR21","unstructured":"European Medicines Agency. CHMP assessment report: Strensiq. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 20 July 2015."},{"issue":"9","key":"535_CR22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/ppul.22527","volume":"47","author":"E Rodriguez","year":"2012","unstructured":"Rodriguez E, Bober M, Davey L, et al. Respiratory mechanics in an infant with perinatal lethal hypophosphatasia treated with human recombinant enzyme replacement therapy. Pediatr Pulmonol. 2012;47(9):917\u201322.","journal-title":"Pediatr Pulmonol."},{"key":"535_CR23","doi-asserted-by":"crossref","unstructured":"Hiremath S, Devendra Kumar VK, Padidela R, et al. Neonatal hypophosphatasia: a rare disorder and new treatment [abstract no. PF.60\u2005]. Arch Dis Child Fetal Neonatal Ed. 2013;98(Suppl 1):A20\u20131.","DOI":"10.1136\/archdischild-2013-303966.069"},{"key":"535_CR24","author":"MP Whyte","year":"2015","unstructured":"Whyte MP, Rockman-Greenberg C, Ozono K, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2015. doi: 10.1210\/jc.2015-3462 .","journal-title":"J Clin Endocrinol Metab."},{"key":"535_CR25","doi-asserted-by":"crossref","unstructured":"Whyte M, Simmons J, Bishop N, et al. Asfotase alfa: sustained efficacy and tolerability in infants and young children with life-threatening hypophosphatasia [abstract no. 69 plus poster]. In: Joint Meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research; 2014.","DOI":"10.1530\/boneabs.3.PP363"},{"issue":"Suppl 1","key":"535_CR26","first-page":"70","volume":"80","author":"CR Greenberg","year":"2013","unstructured":"Greenberg CR, Vockley J, Harmatz P, et al. Asfotase alfa improves skeletal mineralization and respiratory function in infants and young children with hypophosphatasia: results from up to 12\u00a0months \u2018 treatment [abstract no. FC20-1488]. Horm Res. 2013;80(Suppl 1):70.","journal-title":"Horm Res."},{"key":"535_CR27","doi-asserted-by":"crossref","unstructured":"Hofmann C, Rockman-Greenberg C, Harmatz P, et al. Improvement in bone manifestations and respiratory status in infants and young children with HPP treated with asfotase alfa: an update on the ENB-010-10 trial [abstract]. Bone Abstr. 2015;4:OC18.","DOI":"10.1530\/boneabs.4.OC18"},{"key":"535_CR28","unstructured":"Madson KL, Rockman-Greenberg C, Whyte MP, et al. Asfotase alfa: long-term safety and efficacy in children with hypophosphatasia [abstract no. 3808.202]. In: Pediatric Academic Societies Annual Meeting; 2014."},{"key":"535_CR29","unstructured":"Madson K, Rockman-Greenberg C, Melian A, et al. Asfotase alfa: sustained improvements in hypophosphatasia-related rickets, physical function, and pain during 3\u00a0years of treatment for severely affected children [abstract no. 1081]. In: 36th Annual Meeting of the American Society for Bone and Mineral Research; 2014."},{"issue":"Suppl 1","key":"535_CR30","first-page":"29","volume":"82","author":"N Bishop","year":"2014","unstructured":"Bishop N, Simmons J, Lutz R, et al. Hypophosphatasia: gross motor function and height improvement in infants and young children treated with asfotase alfa for up to 3\u00a0years [abstract no. FC2.2]. Horm Res. Paediatr. 2014;82(Suppl 1):29.","journal-title":"Paediatr."},{"key":"535_CR31","unstructured":"Phillips D, Hamilton K, Moseley S, et al. Improved activities of daily living and physical function, with decreased pain, in children with hypophosphatasia treated for three\u00a0years with asfotase alfa: results from the Childhood Health Assessment Questionnaire and the Pediatric Outcomes Data Collection Instrument [abstract no. FRI-224]. Endocr Rev. 2015;36(2)."},{"key":"535_CR32","unstructured":"Phillips D, Hamilton K, Moseley S, et al. Significantly improved muscle strength, running speed, and agility in children with hypophosphatasia treated with asfotase alfa [abstract no. OC4.3 plus oral presentation]. In: 4th Joint Meeting of the European Calcified Tissue Society (ECTS) and the International Bone and Mineral Society (IBMS); 2015."},{"key":"535_CR33","unstructured":"European Medicines Agency. Public summary for opinion on orphan designation: recombinant human tissue nonspecific alkaline phosphatase-Fc-deca-aspartate fusion protein for the treatment of hypophosphatasia. 2008. http:\/\/www.ema.europa.eu\/ . Accessed 27 July 2015."},{"key":"535_CR34","doi-asserted-by":"crossref","unstructured":"Kishnani P, Langman C, Linglart A, et al. A longitudinal, prospective, long-term registry of patients with hypophosphatasia [abstract no. P154]. In: 7th International Conference on Children\u2019s Bone Health; 2015.","DOI":"10.1530\/boneabs.4.P154"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0535-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0535-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0535-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T07:31:16Z","timestamp":1567495876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0535-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,7]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0535-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,7]]}}}